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Abstract
 
Here we present a comprehensive molecular mapping of virus-induced autoimmune B cell
responses obtained by serological identification of antigens by recombinant expression cloning
analysis. Immunoscreening of cDNA expression libraries of various organs (lung, liver, and
spleen) using sera from mice infected with cytopathic (vaccinia virus [VV]) or noncytopathic
(lymphocytic choriomeningitis virus [LCMV]) viruses revealed a broad specificity of the elicited
autoantibody response. Interestingly, the majority of the identified autoantigens have been pre-
viously described as autoantigens in humans. We found that induction of virus-induced autoanti-
bodies of the immunoglobulin G class largely depends on the CD40–CD40L-mediated interaction
between T and B cells. Furthermore, antibody titers against a number of autoantigens were
comparable to the concomitantly induced antiviral antibody response. Comparison of serum
reactivity against a selected panel of autoantigens after infection with VV, LCMV, or vesicular
stomatitis virus showed that the different virus infections triggered distinct autoantibody re-
sponses, suggesting that virus infections may leave specific “autoantibody fingerprints” in the
infected host.
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Introduction
 
Infections with viruses as well as other pathogens lead to
antigen-specific induction of T and B lymphocytes. However,
these usually protective responses are often accompanied by
the appearance of autoantibodies to self-antigens of the host
(1). Autoimmune diseases are usually associated with au-
toantibodies directed against cells of the target tissue (2).
The majority of these antibody responses probably do not
cause direct tissue injury. However, certain conditions may
favor the appearance of autoantibodies that possess a high
pathogenic potential (3, 4).
The concept that viral infections contribute to the devel-
opment of autoimmune diseases is supported by a wide
range of experimental and clinical observations. For example,
infections with pancreatropic viruses such as mumps virus
or Coxsackie virus B often precede the onset of insulin-
dependent diabetes mellitus (5). Virus infections that are
associated with hypergammaglobulinemia such as Epstein-
Barr virus, generally elicit broadly reactive autoantibody
responses with serum antibodies to DNA, cytoskeletal
proteins, or thyroglobulin (6). Furthermore, autoimmune
B cell responses most likely contribute to the extrahepatic
manifestations, such as mixed cryoglobulinemia, glomeru-
lonephritis, and vasculitis, of hepatitis B and C virus infec-
tion (7, 8).
Several mechanisms may account for the generation of
autoantibodies in the cause of viral infections. First, antiviral
antibody responses may cross-react with self-determinants
due to molecular mimicry based on homologies in the
amino acid sequence (9). Second, release of self-antigens
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through direct cytolytic activity of the infectious agent or
by subsequent immune responses directed against infected
cells may precipitate bona fide autoimmunity against anti-
gens of the target tissue. Furthermore, virus infection–asso-
ciated activation of self-reactive “bystander” T and B lym-
phocytes may exacerbate autoimmune reactions (10).
The insights in the pathogenesis of antibody-mediated
autoimmunity have been gained largely by experimental
studies using defined model antigens. However, many as-
pects of virus-induced autoimmunity remain elusive be-
cause the complexity of the virus-induced autoantibody
repertoire is still not completely understood. A particular
drawback is that the molecular nature of autoantigens as
potential drivers of the progressive autoimmune disease has
not yet been systematically dissected.
Detection of human autoantigens has been based on mi-
croscopical detection of autoantibodies reacting with an af-
fected tissue. Subsequent biochemical analyses, frequently
involving immunoprecipitation and immunoblotting, facil-
itated molecular identification of the autoantigen. Identifi-
cation and molecular characterization of self-antigens elicit-
ing linked T and B cell responses has been fostered by 
 
 
 
phage–based expression screening systems (11). For exam-
ple, the serological identification of antigens by recombi-
nant expression cloning (SEREX) approach, originally de-
veloped for the identification of tumor antigens, facilitates
the systematic and unbiased dissection of the autoreactive B
cell repertoire (12–14). For several tumor antigens identi-
fied by SEREX, strong concomitant T helper cell and CTL
responses have been observed in cancer patients, indicating
that this approach is a convenient tool to analyze complex
immune responses against self-antigens (15–18). Further-
more, the suitability of the SEREX approach to define
autoantigens associated with human autoimmune diseases
such as systemic lupus erythematosus and systemic sclerosis
has been shown recently (19–21).
In this study, we used the SEREX technique for molec-
ular mapping of the autoantibody repertoire in mice after
infection with cytopathic and noncytopathic viruses. Our
analysis revealed an intriguingly broad polyclonal autoim-
mune B cell response against mainly intracellular proteins,
including a large number of “SEREX antigens” previously
identified with human sera.
 
Materials and Methods
 
Viruses and Mice.
 
Lymphocytic choriomeningitis virus (LCMV)-
WE was originally obtained from F. Lehmann-Grube (University
of Hamburg, Hamburg, Germany) and was propagated on L929
cells. Recombinant vaccinia virus (VV) expressing vesicular sto-
matitis virus (VSV) glycoprotein (VV-INDG) was provided by B.
Moss (National Institutes of Health, Bethesda, MD) and grown
on BSC 40 cells. VSV Indiana (VSV-IND; Mudd-Summers
isolate) was originally obtained from D. Kolakofsky (University
of Geneva, Geneva, Switzerland). VSV was propagated on baby
hamster kidney 21 cells. Mice were infected with either 200 PFU
LCMV-WE (low dose), 2 
 
  
 
10
 
5 
 
PFU LCMV-WE (high dose),
2 
 
  
 
10
 
6 
 
PFU VV-INDG, or 2 
 
  
 
10
 
6 
 
PFU VSV-IND via i.v. in-
jection. In vivo depletion of CD4 T cells was performed by in-
jection of rat monoclonal antibody (YTS 191.6) on days 
 
 
 
3 and
 
 
 
1 before infection (22). C57BL/6, CD40L-deficient (23), and
IgM-deficient (24) mice were obtained from the Institut fuer
Labortierkunde (University of Zurich, Zurich, Switzerland). All
animals were kept under specific pathogen-free conditions. Ex-
periments were performed with age- (8–12 wk) and sex-matched
animals.
 
Construction of cDNA Expression Libraries.
 
If cDNA expres-
sion libraries are derived from B cell–infiltrated tissues, SEREX
immunoscreening might be seriously hampered by direct binding
of the second antibody to recombinantly expressed Ig transcripts
that may represent the majority of “reactive” clones. These “false
positive” clones can be identified in a prescreening procedure
whereby the membranes are first incubated with enzyme-conju-
gated anti–human IgG antibody (25). To exclude the detection
of false positive clones in our SEREX analysis of virus-induced
murine autoimmune B cell responses, cDNA libraries were gen-
erated from tissues of B cell–deficient mice. Organs from per-
fused B6-
 
 
 
MT mice were shock frozen in liquid nitrogen and
stored at 
 
 
 
80
 
 
 
C. Total RNA was isolated from 0.5–1 g of tissue
using the method described by Chomczynski and Sacchi (26).
Poly(A)
 
  
 
RNA was isolated and used to construct cDNA libraries
using ZAP Express cDNA synthesis kit and ZAP Express Giga-
pack III Gold Cloning kit (Stratagene) as described previously
(27). The libraries consisted of 2–10 
 
  
 
10
 
6 
 
primary recombinants.
2–10 
 
  
 
10
 
5 
 
clones from each library were screened according to
established SEREX protocols.
 
Immunoscreening.
 
Serum was collected from mice at the indi-
cated time points after immunization and stored at 
 
 
 
20
 
 
 
C.
Pooled serum from 10 mice was preabsorbed three times against
bacteria lysed by nonrecombinant ZAP Express phages. The pre-
absorbed serum mix was diluted to a final concentration of 1:500
in 1 
 
  
 
TBS, 1% dry milk, and 0.01% Na-azide.
SEREX immunoscreening has been described elsewhere in
detail (28). In brief, 
 
Escherichia coli
 
 XL1 blue MRF
 
  
 
cells were
transfected with the different expression libraries and plated to an
approximate density of 5,000 PFU/plate. Protein expression was
induced with 0.8 mM isopropyl-
 
 
 
-
 
d
 
-thiogalacoside (IPTG;
Roche Diagnostics). Recombinant proteins were blotted onto
Protran nitrocellulose membranes (Schleicher-Schüll). After wash-
ing in TBST (8.8 g NaCl, 1.4 g Tris, 6 g Tris-HCl, 5 ml Tween
20) and blocking with 5% (wt/vol) milk powder in TBS, mem-
branes were incubated with prediluted (1:500) serum for 12–15 h.
This serum dilution has been chosen because preimmune sera
from naive animals did not show a specific reactivity with single
clones. Antigen–antibody complexes were detected with goat
anti–mouse IgG antibody conjugated to alkaline phosphatase
(Jackson ImmunoResearch Laboratories). Reactive plaques
were visualized with 5-bromo-4-chloro-3-indol-phosphate-tolu-
idin (BCIP; BIOMOL Research Laboratories, Inc.) and ni-
troblue-tetrazoliumchlorid (NBT; BIOMOL Research Labora-
tories, Inc.).
 
Characterization of Positive Clones.
 
Serum-reactive phages
were monoclonalized, isolated, and in vivo excised to plasmid
form using the ExAssist Interference-Resistant Helper Phage ac-
cording to the manufacturer’s instructions (Stratagene). Plasmid
DNA was isolated using commercially available kits (QIAGEN).
The lengths of DNA inserts were determined after double EcoRI
and XhoI restriction endonuclease (Roche Diagnostics) digestion
and size fractionation in standard TAE agarose gel electrophore-
sis. Sequencing was performed using the ABI Prism Cycle Se-
quencing kit (PerkinElmer) and run on an automated ABIPrism 
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DNA sequencer. For sequence analysis, alignments with Gen-
Bank database were performed using the National Center for
Biotechnology Information (NCBI) BLASTN and BLASTX al-
gorithms to identify identities and homologies of genes. Human
orthologues were identified by accessing the Homologene Data-
base through LocusLink (NCBI). In selected cases, orthologues
were confirmed using Mouse Genome Informatics resources
(http://www.informatics.jax.org/searches). Mouse genes for
which no human orthologue is cataloged as well as genes for
which human orthologues have a different HUGO-approved no-
menclature were flagged (see Tables II and III). The Cancer Im-
munome database harboring clones identified by SEREX analy-
sis of human tumors was accessed at http://www2.licr.org/
CancerImmunomeDB and analyzed for representation of human
orthologues of cloned mouse autoantigens.
 
Differential Serological Analysis and Autoantibody Titration.
 
Four
to six phages (1–3 
 
  
 
10
 
2 
 
PFU) encoding monoclonalized indi-
vidual antigens were mixed with wild-type 
 
  
 
ZAP phage as a
control, used to infect exponentially growing 
 
E. coli 
 
XL-1 Blue
MRF
 
 
 
, and separately plated on one 15-cm Petri dish. After
overnight incubation, phage lysates were transferred onto nitro-
cellulose membranes by plaque lift, blocked with 5% (wt/vol)
milk powder in TBS, and incubated overnight with twofold se-
rum dilutions starting at 1:500. Washing and visualization with
NBT and BCIP was performed as described above. Development
of all blots was stopped when control 
 
  
 
ZAP phages started to
show reactivity with sera from naive mice. The sero reactivity
determined in this end-point titration method using crude phage
lysates correlates well with the reactivity seen in Western Blot
analysis with purified recombinant proteins (see below, Fig. S2).
 
Online Supplemental Material.
 
The reactivity of self- and VV
antigens tested with immune versus preimmune sera is shown in
Fig. S1. In Fig. S2, the reactivity of anti-VV sera against recombi-
nant proteins was assessed using semiquantitative Western Blot anal-
ysis. Figs. S1 and S2 are available at http://www.jem.org/cgi/
content/full/jem.20040358/DC1.
 
Results
 
Detection of Immunoreactive Clones and Preliminary Charac-
terization.
 
To achieve broad transcriptional representation,
we generated one library from lung, spleen, and liver tissue.
In addition, to assess whether detection of viral antigens is
feasible using the SEREX method and to assess the impact of
viral infection on the profile of detected autoantigens, we
constructed cDNA libraries from both VV-infected lungs
and ovaries, determined as organs with high viral load. Viral
titers on day 5 after infection were 2–4 
 
  
 
10
 
4 
 
PFU per lung
and 2–6 
 
  
 
10
 
6 
 
PFU per ovary. The cDNA libraries were
screened with pooled sera from C57BL/6 mice infected ei-
ther with 2 
 
  
 
10
 
6 
 
PFU VSV glycoprotein-recombinant VV
or with 200 PFU LCMV-WE. Successful priming of antivi-
ral B cell responses was assessed by VSV neutralization as-
says for VV-INDG and nucleoprotein-specific ELISA for
LCMV. On the peak of the antiviral B cell response (days
14–21), sera were collected and used pooled at 1:500 dilu-
tions for immunoscreening. Between 7 and 10 
 
  
 
10
 
5 
 
clones
from each library were screened and a total of 166 and 26
clones were found to react with sera from VV- or LCMV-
infected mice, respectively (Table I). Sequence analysis and
homology search revealed that these clones represent 40 (VV
infection, Table II) and 14 (LCMV infection, Table III) dif-
ferent antigens. The three libraries derived from different tis-
 
Table I.
 
Summary of the Immunoscreening with Sera from VV- and LCMV-infected Mice
 
Anti-VV sera
 
b
 
Anti-LCMV sera
 
b
 
Library
 
a
 
Screened clones Reactive clones Different antigens
 
c
 
Screened clones Reactive clones Different antigens
Mixed 7 
 
  
 
10
 
5
 
20 8 2 
 
  
 
10
 
5
 
43
Lung/VV 7 
 
  
 
10
 
5
 
42 14 2 
 
  
 
10
 
5
 
43
Ovary/VV 10 
 
  
 
10
 
5
 
104 35 4 
 
  
 
10
 
5
 
18 10
 
a
 
mRNA for the generation of cDNA expression libraries was derived from various tissues of B cell–deficient mice: Mixed, 50% spleen, 30% liver,
20% lung; Lung/VV, VV-infected lung tissue on day 5 after infection; Ovary/VV, VV-infected ovary tissue on day 5 after infection.
 
b
 
C57BL/6 mice infected with 2 
 
  
 
10
 
6 
 
PFU VV-INDG or 200 PFU LCMV-WE were bled on days 14 and 21 after infection. Pooled sera from 10
mice were used for immunoscreening.
 
c
 
Reactive clones representing the same antigen were grouped and scored as one hit because abundant antigens were detected multiple times.
Figure 1. Alignment of selected cDNA clones encoding different regions
in ROCK1 and ROCK2. Nucleotide position of the respective clone is
indicated in parenthesis. 
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Table II.
 
Antigens Detected by IgG Antibodies from Sera of VV-infected Mice
 
No. reactive clones in library
Homologue/identity
 
a
 
Entry in SEREX database
 
b
 
GenBank accession Reactivity
 
c
 
Lung/VV Ovary/VV Mixed
 
Golgi- or ER-associated
 
GOLGB1 Orthologue XM_148244
 
   
 
1
GOLGA4,
Golgi autoantigen 4
Orthologue NM_018748
 
  
 
31 3
4921537D05RIK,
NY-REN-58
Orthologue NM_029852
 
 
 
13 1
 
Surface proteins
 
COL13A1 Homologues
(many other collagens)
NM_007731
 
  
 
2
HMMR,
hyaluronic acid binding protein
Orthologue NM_013552
 
  
 
2
 
Cytoskeleton, structural elements
 
ROCK1 Orthologue NM_009071
 
   
 
16 1
ROCK2 Orthologue NM_009072
 
  
 
6
TPM1, 
 
 
 
-tropomyosin 5b (rat) Orthologue NM_024427
 
  
 
1
MYH6 Homologues
MYH1, 10, 7
NM_010856
 
  
 
51 9
MYH4,
myosin heavy polypeptide 4
Homologues
MYH1, 10, 7
XM_126119
 
 
 
11
2410197A17Rik, PPP1R12C (hu) Homologues
PPP1R12B, 14B, 14C
NM_029834
 
 
 
2
LOC269661, KIAA0635 (hu) Orthologue XM_194221
 
  
 
2
LMNA, Lamin C Orthologue NM_019390
 
 
 
1
CYCLN2, CLIP-115 Orthologue NM_009990
 
  
 
2
DST, BPAG1 (hu) Orthologue NM_010081
 
 
 
21
4933432N21, TSGA10 (hu) Homologue
TSGA2
XM_136734
 
 
 
1
RSN, CLIP-170 Orthologue NM_010081
 
 
 
11
 
Heat shock proteins
 
DNAJA1, hsj2 Orthologue NM_008298
 
  
 
42 3
DNAJC6, hsp40 Homologues
DNAJA1, A2, B1
XM_283995
 
 
 
54
HSPCA, heat shock protein 86 Orthologue NM_010480
 
 
 
11
 
Nuclear factors and DNA binding
 
ATRX,
X-linked nuclear protein
Orthologue NM_009530
 
   
 
1
HOXB1, Homeobox B1 No NM_008266
 
   
 
11
LEK1, CENPF (hu),
centromere protein F
Orthologue XM_129658
 
  
 
1
EIF4GI (hu), translation factor Homologue
EIF4G2
NM_025816
 
  
 
2
 
a
 
NCBI BLASTN and BLASTX algorithms were used to search GenBank database and obtain HUGO-approved nomenclature of clones under in-
vestigation. Mouse genes for which no human orthologues are catalogued as well as genes for which human orthologues have a different HUGO-ap-
proved nomenclature were flagged.
 
b
 
Presence of human orthologues or homologues in the SEREX database (http://www2.licr.org/CancerImmunomeDB).
 
c
 
Seroreactivity of the purified clones was assessed semiquantitatively by comparing the signal obtained with anti-VV serum against the 39-kD immu-
nodominant antigen as reference signal (
 
    
 
). The highest value is shown for antigens with multiple clones. 
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sues appeared complementary in dissecting as many entities
of the autoantibody repertoire as possible. It is worth noting
that the frequency of reactive clones was significantly higher
in the screens with sera from mice infected with the cyto-
pathic VV compared with those from mice infected with the
noncytopathic LCMV.
Infection of mice with VV induced a broad and rather
strong de novo autoimmune B cell response. The clones
reacting with IgG from sera of VV-infected mice repre-
sented 36 autoantigens including Golgi-associated proteins,
cytoskeletal and heat shock proteins, transcription factors,
and proteins involved in DNA replication (Table II).
LCMV infection also induced a broad autoimmune B cell
response against proteins from various intracellular com-
partments (Table III). However, there was only a small
overlap in the specificity, i.e., cardiac myosin heavy chain
   (MYH6) and hyaluronic acid binding protein were
found in both immunoscreens (Tables II and III), suggest-
ing that the two different viruses had elicited distinct pat-
terns of autoreactivity on the B cell level. Most of the anti-
gens were detected repeatedly. Independent clones were
sequenced and aligned against the full-length cDNA
sequence. As exemplified for Rho-associated kinase
(ROCK)1 and ROCK2 in Fig. 1, not all clones were shar-
ing one defined region of the respective protein. Analysis
of the overlaps in all distinct transcripts from these two
molecules that have been found in the screens with anti-
VV serum provides evidence that the de novo autoimmune
response is directed against at least two distinct epitopes in
each antigen (Fig. 1).
Noticing that human orthologues of several of the
identified autoantigens have been reported previously in
SF3B2, splicing factor 3b,
subunit 2
No NM_030109   3
D6ERTD772E, TAX1BP1 (hu) No NM_025816    2
Miscellaneous
OFD1,
oral-facial-digital syndrome 1
Orthologue NM_177429   1
FMO,
flavin-containing monooxygenase 5
No NM_010232   1
NME3,
nucleoside diphosphate kinase DR-nm23
Homologue
NME1,2
NM_019730    2
NY-REN-18 antigen Orthologue NM_016736   3
FES, c-fes protooncogene No XM_133573   11
Hypothetical
1810009B06RIK, KIAA1536 (hu) Orthologue NM_177385    1
D13WSU177E, HSPC111 (hu) No XM_127366    1
D10JHU81E, C21ORF33 (hu) Orthologue NM_138601   11
D530005L17RIK, FLJ25636 (hu) Orthologue NM_177385   11
VV antigens
39-kD immunodominant antigen S71673.1      2
P4b major core antigen M27914      1
62-kD rifampicin-resistance gene M15058, CDS21      1
A-type inclusion protein M61187, CDS2     2
Table II. Antigens Detected by IgG Antibodies from Sera of VV-infected Mice
No. reactive clones in library
Homologue/identitya Entry in SEREX databaseb GenBank accession Reactivityc Lung/VV Ovary/VV Mixed
aNCBI BLASTN and BLASTX algorithms were used to search GenBank database and obtain HUGO-approved nomenclature of clones under in-
vestigation. Mouse genes for which no human orthologues are catalogued as well as genes for which human orthologues have a different HUGO-ap-
proved nomenclature were flagged.
bPresence of human orthologues or homologues in the SEREX database (http://www2.licr.org/CancerImmunomeDB).
cSeroreactivity of the purified clones was assessed semiquantitatively by comparing the signal obtained with anti-VV serum against the 39-kD immu-
nodominant antigen as reference signal (    ). The highest value is shown for antigens with multiple clones.Virus-induced Autoantibodies 642
the context of SEREX analysis of human malignancies,
we systematically assessed the overlap. In fact, orthologues
of 22 of 36 of VV-induced and 7 of 14 LCMV-induced
autoantigens were also represented in the SEREX data-
base. Orthologues of a total of 12 additional autoantigens
were highly homologous and molecularly related to anti-
gens in the SEREX database (COLL13A1, MYH11,
EIF4G1, NME3, etc.), suggesting cross-reactive epitopes.
Thus, in summary, 83 and 79% of the proteins found in
our screens using sera from VV- or LCMV-infected mice,
respectively, represent orthologues of human cancer–asso-
ciated autoantigens.
Table III. Antigens Detected by SEREX Analysis Using Sera of LCMV-infected Mice
Human orthologues in
SEREX databaseb GenBank accession Reactivityc
No. reactive clones in library
Homologue/identitya Lung/VV Ovary/VV Mixed
Golgi- or ER-associated
6030460N08RIK,
TRIP11 (hu),
thyroid hormone receptor interactor 11
Orthologue XM_029327.1    1
Surface proteins
HMMR, hyaluronic acid binding protein Orthologue NM_013552.1    2
LGALS8, galectin 8 Homologues
LGALS1,4,9
NM_018886.1     21
Cytoskeleton, structural elements
MYH11,
smooth muscle myosin heavy chain 11
Homologues
MYH1, 10, 7, 9
NM_013607.1    2
MYH6 Homologues
MYH1, 10, 7, 9
M76600.1   2
NIN, ninein Orthologue NM_008697.1    3
CATNB, CTNNB1 (hu),   catenin Homologues
CTNNBLB1, A
NM_007614.1   1
Nuclear factors and DNA binding
HNRPAB,
CArG box binding factor
Orthologue L36663.1    1
SATB1,
special AT sequence binding protein 1
Orthologue NM_009122.1    2
Miscellaneous
MDM2, mouse double minute clone 2 No NM_010786   1
TRIM2, tripartite motif protein 12 Orthologue NM_030706 1
RRBP1, ribosome receptor isoform Orthologue XM_194049   32
SDCCAG8,
serological colon cancer antigen 8
Orthologue AK017691.1    1
DLAT,
pyruvate dehydrogenase component E2
No NM_145614   1
aNCBI BLASTN and BLASTX algorithms were used to search GenBank database and obtain HUGO-approved nomenclature of clones under in-
vestigation. Mouse genes for which no human orthologues are catalogued as well as genes for which human orthologues have a different HUGO-ap-
proved nomenclature were flagged.
bPresence of human orthologues of autoantigens under consideration in the SEREX database.
cSeroreactivity of the purified clones was assessed semiquantitatively by comparing the signal obtained with anti-VV serum against the 39-kD immu-
nodominant antigen as reference signal (    ). The highest value is shown for antigens with multiple clones.Ludewig et al. 643
Differential Serological Analysis. To investigate the mech-
anisms of virus-induced autoimmune B cell responses in
more detail, six autoantigens and two VV antigens were
selected for differential serological analysis and titration:
mouse homologues of known human autoantigens not rep-
resented in the SEREX database (MYH6 [29] and mac-
rogolgin [GOLGB1; references 30 and 31]), mouse homo-
logues of autoantigens present in the SEREX database
(ROCK1, ROCK2, and hsj2/DNAJA1), the surface mole-
cule procollagen XIII (COL13A1; reference 32), and the
immunodominant VV antigens (39-kD antigen and A-type
inclusion protein). The SEREX technique not only facili-
tates the profiling of autoimmune B cell responses, but also
enables simple and rapid quantification of autoantibody ti-
ters using the recombinant protein in phage lysates. To this
end, replica-plated phages were incubated with serial two-
fold dilutions of serum from virus-infected mice and pro-
cessed according to the standard SEREX protocol. As
shown in Fig. 2 A, infection of C57BL/6 mice with 2  
106 PFU of the cytopathic VV elicited both strong anti-
body responses against the immunodominant VV 39-kD
antigen and the Golgi-associated protein GOLGB1 with ti-
ters of  1:16,000 and 1:16,000, respectively. VV-induced
autoreactivity against MYH6 and ROCK2 was signifi-
cantly lower (Fig. 2 A). It is worthy to note that preim-
mune sera from naive mice did not show specific reactivity
against autoantigens or VV antigens (Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20040358/DC1).
LCMV high dose infection has been shown to induce
strong polyclonal B cell activation with hypergammaglobu-
linemia and elevated autoantibody titers (33). Indeed, de-
spite the rather high initial serum dilution of 1:500, we
found that LCMV-induced IgG antibodies reacted weakly
with the selected autoantigens and with VV antigens (Figs.
2 B and 3 A). However, both high dose (Fig. 2 B) and low
dose (Fig. 3 A) LCMV infection also elicited high titer au-
toantibody responses against several distinct antigens such
as ROCK1 and ROCK2 (Figs. 2 B and 3 A). Low level
LCMV-induced reactivity against VV antigens and self-
antigens such as GOLGB1 was transient and peaked around
day 20 after infection (Fig. 4 A), whereas anti-ROCK2
autoantibodies persisted for  100 d (Fig. 4 B). Similarly,
VV-induced IgG antibodies against VV antigen and self-
antigens persisted at rather high levels until 120 d after in-
fection (Fig. 4). Infection with the cytopathic vesicular sto-
Figure 2. Rapid determination of
seroreactivity pattern after viral infec-
tion.  Phages from clones encoding
for VV 39-kD immunodominant
antigen, MYH6, GOLGB1, and
ROCK2 were mixed with wild-type
phage clones as negative control and
used to transfect E. coli. After transfer
onto nitrocellulose membranes, rep-
lica-plated phages were incubated
with serial twofold dilutions of pooled
serum from (A) mice infected with
2   106 PFU VV (day 14 after infec-
tion) or (B) mice infected with 2  
105 PFU LCMV.
Figure 3. Antibody responses directed against a selected panel of autoanti-
gens (ROCK1 and ROCK 2), hsj2 (DNAJA1), MYH6, COL13A1 and
GOLGB1, and VV antigens (VV39kD, immunodominant antigen; VV
ATI, A-type inclusion protein) as determined on day 21 after infection by
quantitative phage assay. (A) Antibody titers in pooled sera from five
C57BL/6 mice infected with 2   106 PFU VV, 200 PFU LCMV, and
2   106 PFU VSV. (B) The role of T helper cells in the induction of autoan-
tibodies was determined by infection with 2   106 PFU VV of C57BL/6
mice, CD4-depleted mice, or CD40L-deficient mice.Virus-induced Autoantibodies 644
matitis virus induced only weak autoantibody responses
against the selected antigen panel and reactivity against VV
antigens was not detectable (Fig. 3 A). Overall, these data
indicate that virus infections elicit persisting “autoantibody
fingerprints” in the infected host.
To investigate the role of T cell help for virus-induced
autoantibody responses, CD4-depleted C57BL/6 mice (Fig.
2 B) were infected with VV and antibody titers against au-
toantigens and VV antigens were determined. Depletion of
CD4 T cells nearly completely abolished the induction of
both autoviral and antiviral antibody responses (Fig. 3 A).
Similarly, VV-infected mice lacking the ligand for CD40,
which is an essential molecule for Ig isotype switching, did
not develop significant IgG responses against self- or viral
antigens (Fig. 3 B), supporting the notion that virus-induced
autoimmune B cell responses require specific T help deliv-
ered via CD40–CD40L interaction.
Discussion
The SEREX method has been shown to be a potent tool
for the rapid detection and characterization of human tu-
mor–associated antigens (34–36). To better understand
how viral infections impact on the autoantibody profiles
detected by SEREX analysis, we used sera from mice in-
fected either with the cytopathic VV or the noncytopathic
LCMV to screen libraries from different organs. Expression
libraries were constructed from organ tissues of naive and
virus-infected mice to contain not only the respective host
cell transcriptomes, but also viral proteins and host-derived
gene products induced upon infection of eukaryotic cells.
Intriguingly, the majority of the cloned antibody specifici-
ties are not restricted to our experimental mouse models,
but are constituents of the human autoantibody repertoire.
The SEREX approach has been extensively applied by
an international concerted action on a variety of different
human cancer/serum sets. A multitude of tumor-associated
autoantigens has been uncovered (37). However, it soon
became apparent that suitable cancer-related antigens char-
acterized by tumor-selective tissue distribution (38, 39) as
well as by antibodies restricted to sera of tumor patients
(40), comprise the minority of SEREX-identified antigens.
Differential serology (41), i.e., comparatively probing SEREX
antigens with sera from healthy controls and cancer pa-
tients, disclosed that a substantially larger number of anti-
gens identified with SEREX are also recognized at compa-
rable titers by sera of healthy individuals (42, 43). Thus, it is
likely that most of the antibody reactivities mapped with
crude sera of tumor patients occur independently from the
neoplasm.
The data presented here clearly show that many of the
human SEREX antigens have to be regarded as afterglows
of infection-associated immunopathology, and that virus-
induced autoimmunity may obscure truly tumor-specific
antibody responses. The SEREX screening effort, though
initiated with an entirely different aim, has thus en passant
become the only systematic collection providing a nearly
complete picture of comprehensive human adult IgG au-
toantibody repertoires shaped along life by encounters with
triggers as diverse as viruses, tumors, and probably other
causes of immunogenicity and tissue damage. This inter-
pretation is supported by the recent work of T. Blanken-
stein’s group who found that immunization of mice with
tumor cell lysate generates antibody responses against intra-
cellular antigens comparable to those found in human pa-
tients (Blankenstein, T., personal communication).
Furthermore, our data support the notion that virus-
mediated tissue damage leads to a massive anti–self-response
that depends largely on the quality of the initial insult. Pre-
viously sequestered or immunologically ignored antigens
are released and exposed to the immune system as a conse-
quence of direct viral cytopathicity or through immune-
mediated cell destruction. Therefore, the pattern of vi-
rus-induced de novo autoreactivity critically depends on
virus-specific factors such as tissue and target cell tropism,
as well as mechanisms of cell destruction. VV infection, for
example, has been shown to favor the selection of hybrid-
omas secreting autoantibodies against cytoskeletal proteins
(44). The present analysis reveals that VV infection indeed
precipitates strong B cell responses against this set of intra-
cellular proteins, but also against a particular set of cell sur-
face antigens, nuclear proteins, and heat shock proteins.
Production of a broad range of autoantibodies after viral
infection may depend on polyclonal B cell activation such
as bystander cytokines or through presentation of pinocy-
tosed viral antigens to self-reactive B cells (45). However,
our finding that the noncytopathic LCMV induced a dis-
tinct autoantibody pattern compared with the cytopathic
VV infection argues against the interpretation that virus-
induced autoimmune B cell responses are solely the result
Figure 4. Time course of antibody responses against (A) VV proteins
A-type inclusion protein and 39-kD immunodominant antigen, and (B)
anti–self-antigens GOLGB1 and ROCK2 after infection of C57BL/6
mice with 2   106 PFU VV or 200 PFU LCMV. Pooled sera from five
mice were assayed by quantitative phage assay at the indicated time points
after infection.Ludewig et al. 645
of a general and nonspecific activation of the immune sys-
tem. On the contrary, virus-specific patterns of autoreac-
tivity on the B cell level indicate a role for antigen-driven
selection in this process. Nearly all antigens were cloned
multiple times independently. This not only mirrors abun-
dance of the gene product in the screened tissue and high
titer of the respective antibody but, most remarkably, can
also be ascribed to the polyepitopic character of the B cell
response against individual proteins, further supporting the
notion that antigen-specific processes are operant.
We found autoantibody responses to be comparable to
antiviral IgG responses in terms of their titer as well as their
persistence. Most remarkably, intracellular proteins were
clearly dominant, the only exceptions being COL13A1,
hyaluronic acid binding protein, and secreted galectin 8
(LGALS8). Moreover, ubiquitous expression and wide tis-
sue distribution rather than organ specificity is a shared fea-
ture of nearly all cloned autoantigens.
The majority of virus-induced autoantibodies are most
likely not pathogenic, an interpretation that is supported by
the clinical observation that autoantibody responses are fre-
quent but autoimmune disease is rare. However, virus-
induced autoantibodies may become pathogenic when cell
surface structures (46, 47) or intracellular proteins deposited
on the cell membrane are targeted (3, 4, 48). Furthermore,
chronic or recurrent infections with selective virus-induced
tissue destruction may lead to self-perpetuating cycles of
tissue damage and exacerbation of autoimmunity (10).
Therefore, detailed profiling of autoimmune B cell re-
sponses associated with viral infection might be important
for the identification of etiologically significant autoanti-
gens. Furthermore, the identification of virus-induced, spe-
cific autoantibody fingerprints and/or a negative list of
“common” autoantigens may help to improve the predic-
tive value of autoantibody tests (49).
The authors wish to thank Helen Stokes for critical reading of this
manuscript. The authors thank Christoph Huber, Rolf Zinkerna-
gel, and Hans Hengartner for continuous support and discussion.
This work was supported by Kanton of Zürich and the Swiss Na-
tional Science Foundation (no. 32-63415.00 to B. Ludewig) and by
the Deutsche Forschungsgemeinschaft (no. SFB 432 D1 to U. Sahin).
The authors have no conflicting financial interests.
Submitted: 23 February 2004
Accepted: 26 June 2004
References
1. Hansen, K.E., J. Arnason, and A.J. Bridges. 1998. Autoanti-
bodies and common viral illnesses. Semin. Arthritis Rheum.
27:263–271.
2. Lernmark, A. 2001. Autoimmune diseases: are markers ready
for prediction? J. Clin. Invest. 108:1091–1096.
3. Korganow, A.S., H. Ji, S. Mangialaio, V. Duchatelle, R. Pe-
landa, T. Martin, C. Degott, H. Kikutani, K. Rajewsky, J.L.
Pasquali, et al. 1999. From systemic T cell self-reactivity to
organ-specific autoimmune disease via immunoglobulins. Im-
munity. 10:451–461.
4. Okazaki, T., Y. Tanaka, R. Nishio, T. Mitsuiye, A. Mizogu-
chi, J. Wang, M. Ishida, H. Hiai, A. Matsumori, N. Minato,
et al. 2003. Autoantibodies against cardiac troponin I are re-
sponsible for dilated cardiomyopathy in PD-1-deficient mice.
Nat. Med. 9:1477–1483.
5. Jun, H.S., and J.W. Yoon. 2003. A new look at viruses in
type 1 diabetes. Diabetes Metab. Res. Rev. 19:8–31.
6. Misra, R., P.J. Venables, C. Plater-Zyberk, P.F. Watkins,
and R.N. Maini. 1989. Anti-cardiolipin antibodies in infec-
tious mononucleosis react with the membrane of activated
lymphocytes. Clin. Exp. Immunol. 75:35–40.
7. El Serag, H.B., H. Hampel, C. Yeh, and L. Rabeneck. 2002.
Extrahepatic manifestations of hepatitis C among United
States male veterans. Hepatology. 36:1439–1445.
8. Pyrsopoulos, N.T., and K.R. Reddy. 2001. Extrahepatic
manifestations of chronic viral hepatitis. Curr. Gastroenterol.
Rep. 3:71–78.
9. Oldstone, M.B. 1998. Molecular mimicry and immune-
mediated diseases. FASEB J. 12:1255–1265.
10. Vanderlugt, C.L., and S.D. Miller. 2002. Epitope spreading
in immune-mediated diseases: implications for immunother-
apy. Nat. Rev. Immunol. 2:85–95.
11. Andrade, L.E., E.K. Chan, I. Raska, C.L. Peebles, G. Roos,
and E.M. Tan. 1991. Human autoantibody to a novel pro-
tein of the nuclear coiled body: immunological characteriza-
tion and cDNA cloning of p80-coilin. J. Exp. Med. 173:
1407–1419.
12. Old, L.J., and Y.T. Chen. 1998. New paths in human cancer
serology. J. Exp. Med. 187:1163–1167.
13. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Jo-
hannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M.
Pfreundschuh. 1995. Human neoplasms elicit multiple spe-
cific immune responses in the autologous host. Proc. Natl.
Acad. Sci. USA. 92:11810–11813.
14. Tureci, O., U. Sahin, C. Zwick, F. Neumann, and M. Pfre-
undschuh. 1999. Exploitation of the antibody repertoire of
cancer patients for the identification of human tumor anti-
gens. Hybridoma. 18:23–28.
15. Ayyoub, M., D. Rimoldi, P. Guillaume, P. Romero, J.C.
Cerottini, D. Valmori, and D. Speiser. 2003. Tumor-reac-
tive, SSX-2-specific CD8  T cells are selectively expanded
during immune responses to antigen-expressing tumors in
melanoma patients. Cancer Res. 63:5601–5606.
16. Gnjatic, S., D. Atanackovic, E. Jager, M. Matsuo, A. Selva-
kumar, N.K. Altorki, R.G. Maki, B. Dupont, G. Ritter,
Y.T. Chen, et al. 2003. Survey of naturally occurring CD4 
T cell responses against NY-ESO-1 in cancer patients: corre-
lation with antibody responses. Proc. Natl. Acad. Sci. USA.
100:8862–8867.
17. Jager, E., Y. Nagata, S. Gnjatic, H. Wada, E. Stockert, J.
Karbach, P.R. Dunbar, S.Y. Lee, A. Jungbluth, D. Jager, et
al. 2000. Monitoring CD8 T cell responses to NY-ESO-1:
correlation of humoral and cellular immune responses. Proc.
Natl. Acad. Sci. USA. 97:4760–4765.
18. Zeng, G., X. Wang, P.F. Robbins, S.A. Rosenberg, and
R.F. Wang. 2001. CD4( ) T cell recognition of MHC class
II-restricted epitopes from NY-ESO-1 presented by a preva-
lent HLA DP4 allele: association with NY-ESO-1 antibody
production. Proc. Natl. Acad. Sci. USA. 98:3964–3969.
19. Jeoung, D.I., L.E. Bong, S. Lee, Y. Lim, D.Y. Lee, J. Kim,
H.Y. Kim, and S.Y. Wook. 2002. Autoantibody to DNA
binding protein B as a novel serologic marker in systemic
sclerosis. Biochem. Biophys. Res. Commun. 299:549–554.
20. Lim, Y., D.Y. Lee, S. Lee, S.Y. Park, J. Kim, B. Cho, H.Virus-induced Autoantibodies 646
Lee, H.Y. Kim, E. Lee, Y.W. Song, et al. 2002. Identifica-
tion of autoantibodies associated with systemic lupus erythe-
matosus. Biochem. Biophys. Res. Commun. 295:119–124.
21. Schmits, R., B. Kubuschok, S. Schuster, K.D. Preuss, and M.
Pfreundschuh. 2002. Analysis of the B cell repertoire against
autoantigens in patients with giant cell arteritis and polymyal-
gia rheumatica. Clin. Exp. Immunol. 127:379–385.
22. Cobbold, S.P., A. Jayasuriya, A. Nash, T.D. Prospero, and H.
Waldmann. 1984. Therapy with monoclonal antibodies by
elimination of T-cell subsets in vivo. Nature. 312:548–551.
23. Renshaw, B.R., W.C. Fanslow III, R.J. Armitage, K.A.
Campbell, D. Liggitt, B. Wright, B.L. Davison, and C.R.
Maliszewski. 1994. Humoral immune responses in CD40
ligand–deficient mice. J. Exp. Med. 180:1889–1900.
24. Brundler, M.A., P. Aichele, M. Bachmann, D. Kitamura, K.
Rajewsky, and R.M. Zinkernagel. 1996. Immunity to viruses
in B cell-deficient mice: influence of antibodies on virus persis-
tence and on T cell memory. Eur. J. Immunol. 26:2257–2262.
25. Tureci, O., H. Schmitt, N. Fadle, M. Pfreundschuh, and U.
Sahin. 1997. Molecular definition of a novel human galectin
which is immunogenic in patients with Hodgkin’s disease. J.
Biol. Chem. 272:6416–6422.
26. Chomczynski, P., and N. Sacchi. 1987. Single-step method
of RNA isolation by acid guanidinium thiocyanate-phenol-
chloroform extraction. Anal. Biochem. 162:156–159.
27. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Jo-
hannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M.
Pfreundschuh. 1995. Human neoplasms elicit multiple spe-
cific immune responses in the autologous host. Proc. Natl.
Acad. Sci. USA. 92:11810–11813.
28. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Jo-
hannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M.
Pfreundschuh. 1995. Human neoplasms elicit multiple spe-
cific immune responses in the autologous host. Proc. Natl.
Acad. Sci. USA. 92:11810–11813.
29. Pummerer, C.L., K. Luze, G. Grassl, K. Bachmaier, F.
Offner, S.K. Burrell, D.M. Lenz, T.J. Zamborelli, J.M. Pen-
ninger, and N. Neu. 1996. Identification of cardiac myosin
peptides capable of inducing autoimmune myocarditis in
BALB/c mice. J. Clin. Invest. 97:2057–2062.
30. Seelig, H.P., P. Schranz, H. Schroter, C. Wiemann, and M.
Renz. 1994. Macrogolgin–a new 376 kD Golgi complex outer
membrane protein as target of antibodies in patients with rheu-
matic diseases and HIV infections. J. Autoimmun. 7:67–91.
31. Toki, C., T. Fujiwara, M. Sohda, H.S. Hong, Y. Misumi,
and Y. Ikehara. 1997. Identification and characterization of
rat 364-kDa Golgi-associated protein recognized by autoanti-
bodies from a patient with rheumatoid arthritis. Cell Struct.
Funct. 22:565–577.
32. Hagg, P., M. Rehn, P. Huhtala, T. Vaisanen, M. Tamminen,
and T. Pihlajaniemi. 1998. Type XIII collagen is identified as a
plasma membrane protein. J. Biol. Chem. 273:15590–15597.
33. Hunziker, L., M. Recher, A.J. Macpherson, A. Ciurea, S.
Freigang, H. Hengartner, and R.M. Zinkernagel. 2003. Hy-
pergammaglobulinemia and autoantibody induction mecha-
nisms in viral infections. Nat. Immunol. 4:343–349.
34. Tureci, O., U. Sahin, and M. Pfreundschuh. 1997. Serologi-
cal analysis of human tumor antigens: molecular definition
and implications. Mol. Med. Today. 3:342–349.
35. Old, L.J., and Y.T. Chen. 1998. New paths in human cancer
serology. J. Exp. Med. 187:1163–1167.
36. Preuss, K.D., C. Zwick, C. Bormann, F. Neumann, and M.
Pfreundschuh. 2002. Analysis of the B-cell repertoire against
antigens expressed by human neoplasms. Immunol. Rev. 188:
43–50.
37. Jongeneel, V. 2001. Towards a cancer immunome database.
Cancer Immun. 1:3.
38. Chen, Y.T., and L.J. Old. 1999. Cancer-testis antigens: tar-
gets for cancer immunotherapy. Cancer J. Sci. Am. 5:16–17.
39. Old, L.J. 2001. Cancer/testis (CT) antigens-a new link be-
tween gametogenesis and cancer. Cancer Immun. 1:1.
40. Stockert, E., E. Jager, Y.T. Chen, M.J. Scanlan, I. Gout, J.
Karbach, M. Arand, A. Knuth, and L.J. Old. 1998. A survey
of the humoral immune response of cancer patients to a panel
of human tumor antigens. J. Exp. Med. 187:1349–1354.
41. Krause, P., O. Tureci, P. Micke, R. Buhl, C. Huber, and U.
Sahin. 2003. SeroGRID: an improved method for the rapid
selection of antigens with disease related immunogenicity. J.
Immunol. Methods. 283:261–267.
42. Scanlan, M.J., S. Welt, C.M. Gordon, Y.T. Chen, A.O.
Gure, E. Stockert, A.A. Jungbluth, G. Ritter, D. Jager, E.
Jager, et al. 2002. Cancer-related serological recognition of
human colon cancer: identification of potential diagnostic
and immunotherapeutic targets. Cancer Res. 62:4041–4047.
43. Scanlan, M.J., I. Gout, C.M. Gordon, B. Williamson, E.
Stockert, A.O. Gure, D. Jager, Y.T. Chen, A. Mackay, M.J.
O’Hare, et al. 2001. Humoral immunity to human breast
cancer: antigen definition and quantitative analysis of mRNA
expression. Cancer Immun. 1:4.
44. Dales, S., R.S. Fujinami, and M.B. Oldstone. 1983. Infection
with vaccinia favors the selection of hybridomas synthesizing
autoantibodies against intermediate filaments, one of them
cross-reacting with the virus hemagglutinin. J. Immunol. 131:
1546–1553.
45. Hunziker, L., M. Recher, A.J. Macpherson, A. Ciurea, S.
Freigang, H. Hengartner, and R.M. Zinkernagel. 2003. Hy-
pergammaglobulinemia and autoantibody induction mecha-
nisms in viral infections. Nat. Immunol. 4:343–349.
46. Mazza, G., M.E. el Idrissi, J.P. Coutelier, A. Corato, C.J. El-
son, C.J. Pfau, and M.J. Day. 1997. Infection of C3HeB/FeJ
mice with the docile strain of lymphocytic choriomeningitis
virus induces autoantibodies specific for erythrocyte Band 3.
Immunology. 91:239–245.
47. Nardi, M.A., L.X. Liu, and S. Karpatkin. 1997. GPIIIa-(49-
66) is a major pathophysiologically relevant antigenic deter-
minant for anti-platelet GPIIIa of HIV-1-related immu-
nologic thrombocytopenia. Proc. Natl. Acad. Sci. USA. 94:
7589–7594.
48. Matsumoto, I., M. Maccioni, D.M. Lee, M. Maurice, B.
Simmons, M. Brenner, D. Mathis, and C. Benoist. 2002.
How antibodies to a ubiquitous cytoplasmic enzyme may
provoke joint-specific autoimmune disease. Nat. Immunol. 3:
360–365.
49. Robinson, W.H., C. DiGennaro, W. Hueber, B.B. Haab,
M. Kamachi, E.J. Dean, S. Fournel, D. Fong, M.C. Gen-
ovese, H.E. de Vegvar, et al. 2002. Autoantigen microarrays
for multiplex characterization of autoantibody responses. Nat.
Med. 8:295–301.